MedTech Dive March 27, 2024
Nick Paul Taylor

William Blair analysts called the clearance a positive surprise, explaining that the FDA has denied several therapies in the patient population.

Dive Brief:

  • Neuronetics received 510(k) clearance to use its transcranial magnetic stimulation (TMS) device to treat adolescents with major depressive disorder (MDD).
  • The Food and Drug Administration expanded the label to cover people aged 15 to 21 years after Neuronetics shared real-world data linking its device to clinically meaningful improvements in the severity of depression in 78% of patients, according to the company’s Monday announcement.
  • William Blair analysts called the clearance a positive surprise, explaining that the FDA has denied several therapies in the patient population. Neuronetics competes with Brainsway, Apollo TMS, Magstim, Magventure, CloudTMS and Nexstim for...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies, Medical Devices
Medicare Coverage Of Medical Technologies In A New Era
This year's top congressional medical technology priorities
Boston Scientific to acquire devicemaker: 3 things to know
Everything You Need To Know Before Getting An RFID Implant - 3
State Licensing Spotlight - Prescription medical device manufacturers & distributors: Regulatory considerations applicable to medical devices versus drugs

Share This Article